Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anastasia Krasko
Institution:
Centro de Investigación Médica Aplicada
Observed institutions:
Universitat Pompeu Fabra,
Centro de Investigación Médica Aplicada
ORCID:
0009-0002-8287-2998
Observed ORCID:
0009-0002-8287-2998
OpenAlex ID:
A5118330219
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
·
Clinical Cancer Research
·
5
A novel mismatch repair deficient lung adenocarcinoma model for immunotherapy research
2025
·
Ivan Zadra
, Etna Abad
, et al.
·
Cancer Letters
·
3
Figure S5 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Data from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Supplementary Appendix from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Show more works
View as search
Works count:
13
Citation count:
8
H-index:
2
I10-index:
Year
Topic
Type